Lv73
4210 积分 2021-08-04 加入
Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study
5小时前
已完结
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy
4天前
已完结
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
4天前
已完结
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
5天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
15天前
已关闭
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
15天前
已完结
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
1个月前
已关闭
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
1个月前
已完结
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
1个月前
已完结
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
1个月前
已完结
皖公网安备34019202002308
